Fidelity, Valor pool $71.8M for Jeff Aronin's plan to reformulate a generic for butterfly skin disease at Castle Creek Pharma
Jeff Aronin is back.
To be sure, Aronin didn’t exactly go away. The former Marathon Pharmaceuticals CEO merely sold off a controversial drug, shuttered his embattled company, and ducked from the scandal (we’ll explain). But he held on as chairman and chief executive of Paragon Biosciences, which has continued incubating rare disease ventures like Marathon.
For the first time since last May, though, Aronin is now ready to hustle another repurposed orphan drug through the regulatory process — with $71.8 million he just raised.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
